American Electric Power (AEP) was downgraded to hold from buy at Jefferies. The valuation is less attractive, based on a $67 price target, Jefferies said.
Arrow (ARW) was downgraded to neutral from buy at Goldman Sachs. $63 price target. The company is seeing higher inventory and a weaker manufacturing environment, Goldman said.
Ascena Retail (ASNA) was downgraded to sector perform at RBC Capital. $7 price target. The company has limited sales visibility and is losing credibility with investors, RBC said.
Ascena Retail was downgraded to perform at Oppenheimer. The company is seeing lower traffic across the board, Oppenheimer said.
Columbia Sportswear (COLM) was upgraded to buy from hold at Canaccord Genuity. $72 price target. The company is set up well for the second half of the year and margins should recover, Canaccord said.
Flextronics (FLEX) was upgraded to buy at Goldman. $16 price target. Earnings estimates were also increased, as the company is entering new markets, Goldman said.
HD Supply (HDS) was downgraded to sector perform from outperform at RBC Capital. $35 price target. It will likely take several quarters to fix the supply chain and restore investor confidence, RBC said.
IAC/InterActive (IACI) was upgraded to outperform from sector perform at Wells Fargo. The valuation is more attractive, as the market is discounting the Match holdings, Wells said.
Jabil Circuit (JBL) was upgraded to neutral from sell at Goldman Sachs. $21 price target. The company is seeing higher demand from key customers, Goldman said.
JD.com (JD) was downgraded to neutral from buy at MKM Partners. $27 price target. The company is facing increased competition, MKM said.
Kirby (KEX) was upgraded to outperform at RBC Capital. $68 price target. Industry fundamentals are near a bottom and should rebound in the coming quarters, RBC said.
PNM Resources (PNM) was upgraded to buy from hold at Jefferies. $37.50 price target. Sentiment is overly negative ahead of the upcoming rate case decision, Jefferies said.
Sarepta (SRPT) was upgraded to hold from underperform at Jefferies. $50 price target. Eteplirsen received accelerated approval from the FDA, Jefferies said.
Wells Fargo (WFC) was upgraded to overweight from equal-weight at Morgan Stanley. $53 price target. The valuation is more attractive, as the stock is trading at 11x earnings and offers a 3.5% dividend yield, Morgan Stanley said.